An FDA database analysis shows that reported adverse skin events after GLP-1 receptor agonist use are rare but can include rash and pruritus, highlighting a need for further research, according to a ...

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the ...

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...

Trulicity (dulaglutide), a once-weekly subcutaneous injection, has been approved by the U.S. Food and Drug Administration to improve glycemic control in adults with type 2 diabetes along with diet and ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes had larger decreases in HbA1c at 28 weeks with mazdutide vs. dulaglutide. More than ...

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...

The diabetes drug dulaglutide (Trulicity) may significantly lower a woman’s risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published ...

No significant increase in hazard ratios seen for GI events for semaglutide vs dulaglutide, tirzepatide vs dulaglutide, tirzepatide vs semaglutide. HealthDay News For patients with type 2 diabetes ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...

Eli Lilly and Company is running a study called “A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in ...